Pasireotide
Full Name：Pasireotide/p>
Cas No：396091-73-9
Molecular Formular: C58H66N10O9
Molecular Weight: 1047.21
Sequence：Cyclo[(2S)-2-phenylglycyl-D-tryptophyl-L-lysyl-O-(phenylmethyl)-L-tyrosyl-L-phenylalanyl-(4R)-4-[[[(2-aminoethyl)amino]carbonyl]oxy]-L-prolyl]
Purity：≥98.0%
Here is the chemical structural formula
Application field: Pasireotide (SOM230, trade name Signifor) is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs.